34 results about "Immunologic assay" patented technology

Provided is an immunological measurement method for measuring a target substance in a sample, wherein an antigen-antibody reaction is performed at least once in the presence of an enzyme that specifically decomposes immunoglobulin A, abbreviated as IgA.

The invention provides a kit for quantitatively detecting VEGF (Vascular Endothelial Growth Factor) by using a chemiluminescence method as well as a preparation method and a detection method of the kit. The kit comprises a VEGF reagent 1 which is a diluent 1; the VEGF reagent 2 comprises a peroxidase-labeled VEGF antibody and a diluent 2; the VEGF coated plate comprises a VEGF coated antibody, a diluent 1, a diluent 3, a diluent 4 and a chemiluminescent plate; the diluent 1 is a phosphate buffer solution; the diluent 2 is a Tris buffer solution containing fetal calf serum and an HRP enzyme stabilizer; the diluent 3 is a carbonate buffer solution; and the diluent 4 is a phosphate buffer solution containing sodium caseinate and a light-emitting plate stabilizer. According to the detection kit, the double antibody sandwich method immunoassay principle is combined with enzyme labeling and catalytic chemiluminescence immunoassay, the content of the VEGF is quantitatively determined, the detection kit can be prepared with low cost, accurate determination of the VEGF can be achieved, and the detection kit has high sensitivity and good stability.

Extracellular vesicles and / or exosomes (EVs) remain sparsely studied in hemorrhagic transformations, including stroke and intracranial hemorrhages and could provide key insights into stroke pathophysiology. We assessed plasma levels of neuron-derived EVs (NDEs), astrocyte-derived EVs (ADEs), and oligodendrocyte-derived EVs (ODEs) in 58 patients 5, 15, and 30 days post-ischemic stroke along with 46 matched controls using sandwich immunoassays. Hemorrhagic transformation was a better predictor of ADE levels than lesion volume in linear regression models. These findings suggest that ADE levels are preferentially increased over the first month post-stroke compared to EVs from other neural cell types. ADEs may be of additional interest as biomarkers of blood-brain barrier breakdown to predict hemorrhagic transformation at earlier time points after stroke.

The presently described and claimed technology relates immunoassay methods of assessing a subject's Alzheimer's Disease status and zygosity for the APOE ε4 allele.

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

This invention provides novel and improved DHEAS assay reagents and assays, as well as methods for manufacturing and using them to detect DHEAS levels in biological samples. [Solution] An immunoassay reagent containing a dehydroepiandrosterone sulfate-fluorescein (DHEAS-FITC) conjugate or a dehydroepiandrosterone sulfate-carboxymethoxylaminodimethylacridinium ester (DHEAS-CMO-DMAE) conjugate is disclosed. Immunosay kits and devices containing one or more DHEAS conjugates are also disclosed. Methods for producing and using DHEAS conjugates are further disclosed.

Described herein are devices and methods for improved detection and quantitation of biomolecules. Devices and methods may include a microfluidic biosensing platform for measuring electrical impedance changes in the presence of target analytes from sinusoidal input voltages to improve the sensitivity of immunoassays. In one embodiment, the described devices and methods may provide a point-of-care immunoassay platform for quantitative diagnostics using signal-enhancing microparticles to improve sensitivity and the limit-of-detection.

The present invention addresses the problem of providing a transparent conductive film that can be used in a rapid and simple inspection device, and a biochip therefor. In particular, provided are a transparent conductive film for immunoassay using electrochemiluminescence and a biochip thereof. Provided is a laminate comprising a transparent conductive film and a porous film laminated on the transparent conductive film, in which the porous film has permeability to an electrolyte solution.

The present disclosure is directed to methods for fabricating cellulose-based microneedles with exceptional wicking properties which can be used for rapid extraction of dermal interstitial fluid (ISF). Microneedle arrays are fabricated through a combination of compression molding and laser etching, utilizing microcrystalline cellulose, a biocompatible material with excellent wicking properties. These microneedles are mechanically robust and can autonomously extract fluid from the skin without the need for external instruments. As such, they can be directly integrated with paper-based lateral flow immunoassays for point-of-care disease detection.

A waste bag for biological waste from a blood analysis device is provided, as well as a cartridge including the waste bag, and a blood analysis device including the bag or the cartridge. The bag includes an envelope, a vent on an upper surface of the envelope for discharging gas, and an opening for receiving liquid waste and gas waste. The bag includes a superabsorbent polymer contained in the envelope, the superabsorbent polymer being in the form of beads.

The invention relates to the field of immunoassays, in particular to the field of immunomolecular assays. The present invention provides an internal control for an immunomolecular assay, such as a dual recognition immunoassay or a proximity ligation assay. The internal control comprises a synthetic peptide having the following formula (I): R1-Z-R2 (I) wherein:-Z is a spacer consisting of 1 to 3 non-natural amino acids; -R1 and R2 are two different peptide moieties wherein the first peptide moiety of R1 or R2 comprises a Lys tag and the second peptide moiety comprises a His tag.

The invention relates to an immunoassay reagent for dengue fever NS1 antigen detection and a preparation method thereof. According to the self-driven micro-fluidic chip, an up-conversion luminescent nano material (UCP) is adopted to mark a dengue fever NS1 antigen specific antibody. The invention further relates to a testing and using method of the up-conversion luminescence method self-driven micro-fluidic chip, the method is used for quantitatively determining the content of the dengue NS1 antigen, the method has the advantages of being short in detection period, high in sensitivity and low in background interference, and support is provided for prevention, diagnosis and treatment of dengue.

Predicting treatment benefits of immune checkpoint inhibitor drugs (ICIs) without resorting to advanced genomic or immunologic assays is a major unmet clinical need. This disclosure provides a predictive model using machine-learning approaches based on routine laboratory test results in clinical practice.

Provided are composite particles having excellent rigidity and visibility.　According to the present invention, provided are composite particles comprising resin particles and metal particles. The resin particles each include a core portion and a shell layer that covers a surface of the core portion. The glass transition temperature of the core portion is 50 to 200°C. The glass transition temperature of the shell layer is -100 to 0°C. With respect to 100 vol% of the total of the metal particles, 80 to 100 vol% of the metal particles are included in the shell layer or present on a surface of the shell layer.

A flowrate-controlled microfluidic system, microfluidic devices for on-cartridge bioanalysis, and an immunoassay method are described. The flowrate-controlled microfluidic implements automation code to run an immunoassay workflow with accurate metering. Methods may include one or more fluidics operations or steps defined by the software code, including loading, incubation, washing, and analysis of assay samples at a sensor region, such as an optical sensor region to be analyzed by an optical imaging system or instrument.

To provide a production method for an immunological measurement reagent containing an insoluble carrier, which is able to prevent a change in sensitivity during the storage of the immunological measurement reagent containing the insoluble carrier, a storage method for improving the storage stability of the immunological measurement reagent containing the insoluble carrier, an immunological measurement reagent containing the insoluble carrier, which has improved storage stability, and a measurement method for a substance to be measured using the immunological measurement reagent.SOLUTION: A production method for an immunological measurement reagent containing an insoluble carrier includes a step 1 of storing, at 11°C to 60°C, an insoluble carrier carrying an antigen or an antibody against a substance to be measured; and a step 2 of storing the insoluble carrier at 2°C to 10°C after the step 1.SELECTED DRAWING: None

Provided herein are compositions and methods related to improved assays for determining the condition of neurodegenerative disease and providing treatment. Also provided herein are compositions and methods comprising improved antibodies for assays, including immunoassays for diagnosing Alzheimer's disease and providing treatment.

This invention provides an immunological assay method capable of suppressing nonspecific reactions caused by immunoglobulin M, abbreviated as IgM, contained in a sample for measurement, and reagents used in this immunological assay method. [Solution] The present invention provides an immunological assay method for measuring a target substance in a sample, comprising performing an antigen-antibody reaction at least once in the presence of an enzyme that specifically degrades IgM, and an immunological assay reagent used in the immunological assay method, comprising an enzyme that specifically degrades IgM.

A labeled antibody according to the present invention is obtained by using a linker to bind a full-length antibody and a labeling substance. The linker is formed by binding a first reactive group of a crosslinking agent to the full-length antibody and binding a second reactive group of the crosslinking agent to the labeling substance. The molecular weight of the labeling substance is 10,000 or greater, and the molecular weight of the crosslinking agent is 270 to 1350.

An apparatus for performing immunometric tests is disclosed. The apparatus has a housing element configured to house a plurality of single sample test devices and includes housings for a solid phase, a sample to be analyzed, and reagents, means for acting on the housing element to allow the execution of the desired immunometric test, and a control unit for managing the apparatus. The apparatus includes means for the automatic execution of different immunometric tests, including a detector for executing Enzyme-Linked Immunosorbent Assay (ELISA) tests, a detector for executing Chemiluminescent Immunoassay (CLIA) tests; and an image detector in communication with the control unit for acquiring and processing images of the sample.

Provided are compounds, compositions, kits, systems, devices, and methods for improving an assay such as, for example, a multiplexed PCR assay (e.g., a multiplexed immuno-PCR assay). A solid support (e.g., a bead) may be provided according to some embodiments of the present invention. The solid support may comprise an encoding agent (e.g., a dye), a nucleic acid sequence (e.g., an oligonucleotide and / or primer); and a molecular recognition element (e.g., an antibody). A detection reagent may be provided according to some embodiments of the present invention. The detection reagent may comprise a molecular recognition element (e.g., an antibody) and a nucleic acid tag. In some embodiments, at least a portion of the nucleic acid sequence of the solid support and at least a portion of the nucleic acid target tag of the detection reagent are configured to participate in a nucleic acid amplification process. A solid support and detection reagent may bind to the same target, thereby forming a reagent pair.

The present invention relates to a synthetic saccharide of general formula (I) that is related to Porphyromonas gingivalis lipopolysaccharide specifically the O-antigen, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Porphyromonas gingivalis bacteria. Another aspect of the present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I).

The present invention relates to a synthetic saccharide of general formula (I) that is related to Porphyromonas gingivalis lipopolysaccharide specifically the O-antigen, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Porphyromonas gingivalis bacteria. Another aspect of the present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I).

A method of forming a solution for a mycolic acid antigen immobilized on a substrate is provided. The method comprises heating a mixture of mycolic acid and a polar organic solvent to a temperature above the melting point of mycolic acid, thereby preparing a solution of a mycolic acid antigen in a polar solvent, where the solution is a micellar solution.

An apparatus for performing immunometric tests is described. The apparatus includes a housing element which receives and allows tests on a single use-type for a single sample test device, a reaction well containing a solid phase, a plurality of wells for reagents, a well for a sample to be analyzed, a control unit for managing the apparatus, and an image detector for acquiring images of the reaction well in communication with the control unit. The control unit processes the acquired images and performs a macroarray test relative to the sample in the test device. During processing, the control unit identifies at the reaction well of the test device, points of a matrix that includes points of analysis related to a specific biomarker that represent measurement parameters of the macroarray test, and performs the macroarray test on the basis of the points. A corresponding method and use procedure are also disclosed.

Described herein are apparatuses and methods for the processing and / or measurements of chemical or biochemical samples on a digital microfluidic device. Also described are methods to configure and operate the modules for efficient processing and measurements of the samples on the device. The apparatus can be used in applications such as DNA / RNA / protein / cell concentration / purification, real-time PCR, isothermal amplification, immunoassay, cell-based assay, library preparation for NGS sequencing, etc.

To provide methods of producing anti-lutein antibodies and detecting lutein by immunoassay, and to provide a kit therefor.SOLUTION: A method of the present invention for detecting lutein by immunoassay comprises a step of bringing a sample containing lutein with an anti-lutein antibody to form an antigen-antibody reaction product containing a complex of the lutein in the sample and the antibody.SELECTED DRAWING: None

The present invention addresses the problem of providing: a sensitizer for immunological measurement with which the problem of salting out in immunological measurement is solved; a kit for immunological measurement, the kit comprising said sensitizer for immunological measurement; and an immunological measurement method using said sensitizer for immunological measurement. The present invention provides a sensitizer for immunological measurement, the sensitizer comprising a copolymer that contains a repeating unit represented by formula [1] and a repeating unit represented by formula [2] or [3]. In the formulae, each group has the definition described in the specification.

Analysis of cell populations for both research and clinical applications such as cell therapy is often performed on whole blood that is close to 24 hours old. The reason for this is that the analysis site is removed from the blood draw site so that blood must be shipped overnight to the analysis site. During the 24-hour shipping period granulocytes, primarily neutrophils, breakdown into cell debris including release of nucleic acids into the blood. Such debris is known to interfere with immunological assays and with rethawing following freezing of samples. There is a need for a method and apparatus to solve this issue. The invention disclosed herein solves the issue. Following blood draw at the draw site the neutrophils are removed using an apparatus that draws blood into a tube that contains anti-CD15 bound to nickel magnetic particles. Following mixing the tube is placed in a magnetic field and then while still in the magnetic field the blood with neutrophils removed is transferred into a new tube for shipment to the analysis site.